Business
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a large unmet-need market LEXINGTON, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT) today announced that new translational data supporting the role of invariant natural killer T (iNKT) cells in idiopathic pulmonary fibrosis (IPF) were presented at the Eme
About this update from Mink Therapeutics, Inc.
[{"type":"image","alt":"MiNK Therapeutics","displaySize":"","headline":null,"caption":"MiNK Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zvDa2P.MLQrfKYIZ2UPPSQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645","width":300,"height":116}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPF","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Findings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration strategies in IPF, a large unmet-need market","length":147,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":243,"olType":false},{"type":"text","content":"LEXINGTON, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT) today announced that new translational data supporting the role of invariant natural killer T (iNKT) cells in idiopathic pulmonary fibrosis (IPF) were presented at the Emerging Cell Therapies Meeting of the Keystone Symposia on Molecular and Cellular Biology, taking place February 1–4, 2026, in Banff, Alberta, Canada.","length":404,"tagName":"p"},{"type":"text","content":"The data, presented by Dr. Terese Hammond, Head of Pulmonary and Inflammatory Diseases at MiNK Therapeutics and a Pulmonary and Critical Care physician, demonstrate a significant depletion of invariant natural killer T (iNKT) cells in lung-associated lymph nodes from patients with end-stage idiopathic pulmonary fibrosis (IPF), supporting a mechanistic role for iNKT insufficiency in advanced disease.","length":402,"tagName":"p"},{"type":"text","content":"“This work provides direct human tissue evidence that iNKT insufficiency is present in advanced IPF,” explained Dr. Terese Hammond. “When considered alongside our prior clinical experience demonstrating immunomodulatory and tissue repair–associated activity of iNKT cell therapy in acute lung injury and ARDS, these findings support the broader potential of MiNK’s iNKT platform to address chronic immune-mediated lung disease.”","length":428,"tagName":"p"},{"typ...